Observational cohort study of HIV-infected African children

Miriam K Laufer1, Joep J G van Oosterhout, M Arantza Perez

  • 1Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD, USA.

Insights

Children identified with HIV through voluntary counseling and testing (VCT) experienced high illness and death rates. Early interventions like trimethoprim-sulfamethoxazole and antiretroviral therapy may improve outcomes for this vulnerable pediatric population.

Area of Science:

  • Pediatric infectious diseases
  • HIV/AIDS research
  • Public health in developing nations

Background:

  • Limited data exists on children with HIV identified through voluntary counseling and testing (VCT).
  • Existing research primarily focuses on children identified via mother-to-child transmission (MTCT) studies.
  • This study addresses a unique, under-described cohort of HIV-infected children.

Purpose of the Study:

  • To describe the characteristics and outcomes of children diagnosed with HIV through VCT.
  • To identify risk factors associated with mortality in this specific pediatric HIV cohort.
  • To inform potential interventions for improving the health of HIV-infected children identified via VCT.

Main Methods:

  • Children diagnosed with HIV through VCT were enrolled in a prospective study.
  • Monthly evaluations were conducted, with participants encouraged to seek care for any illness.
  • Detailed clinical assessments were performed for all reported illnesses.

Main Results:

  • Forty-five children were enrolled; 33% presented with serious acute disease at enrollment.
  • Symptomatic malaria and pneumonia were the most frequent diagnoses.
  • The pediatric cohort exhibited higher morbidity and a 22% mortality rate, significantly exceeding that of a simultaneous adult study.

Conclusions:

  • Malawian children diagnosed with HIV via VCT face substantial morbidity and mortality.
  • Undernutrition and low CD4 cell counts are independent predictors of increased mortality risk.
  • Prophylactic trimethoprim-sulfamethoxazole and access to antiretroviral therapy are crucial for improving outcomes in this population.
Abstract